title: Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study.
abstract: Microangiopathy-related cerebral damage (MARCD) represents a common incidental MRI observation in the elderly. The risk factors of such findings are widely unknown. We therefore performed MRI in 349 randomly selected volunteers (ages 50 to 70 years) without neuropsychiatric disease, and evaluated the association of MARCD with conventional and recently suggested cerebrovascular risk factors such as apolipoprotein E genotypes, plasma concentrations of essential antioxidants and anticardiolipin antibody titres. MARCD was defined as evidence of early confluent and confluent deep white matter hyperintensities and lacunes. It was present in 71 (20.3%) subjects. Individuals with MARCD were older than those without such findings (62.7 years vs 59.6 years; P=0.0001). They had a higher rate of arterial hypertension (45.1% vs 28.1%; P=0.006) and cardiac disease (50.7% vs 37.1%; P=0.04), higher systolic blood pressure readings at exam (144.4 mmHg vs 136.7 mmHg; P=0.004), and higher serum fibrinogen concentrations (327.1 mg/dl vs 292.5 mg/dl; P=0.001). Their levels of total cholesterol (217.6 mg/dl vs 231.2; P=0.009), apolipoprotein A-I (167.3 mg/dl vs 177.4 mg/dl, P=0.02), lycopene (0.17 micromol/l vs 0.24 micromol/l; P=0.003), retinol (1.91 micromol/l vs 2.10 micromol/l; P=0.02) and alpha-tocopherol (27.55 micromol/l vs 31.14 micromol/l; P=0.001) were significantly lower. Forward stepwise regression analysis created a model of independent predictors of MARCD with age entering first (odds ratio 2.01/10 years), fibrinogen second (odds ratio 2.45/100 mg/dl), alpha-tocopherol third (odds ratio 0.55/10 micromol/l), and arterial hypertension fourth (odds ratio 1.96). The association of MARCD with various treatable clinical conditions may have preventive implications.
authors.affiliation: Department of Neurology, Karl-Franzens University Graz, Austria.
authors.forename: R
authors.initials: R
authors.lastname: Schmidt
authors.forename: F
authors.initials: F
authors.lastname: Fazekas
authors.forename: M
authors.initials: M
authors.lastname: Hayn
authors.forename: H
authors.initials: H
authors.lastname: Schmidt
authors.forename: P
authors.initials: P
authors.lastname: Kapeller
authors.forename: G
authors.initials: G
authors.lastname: Roob
authors.forename: H
authors.initials: H
authors.lastname: Offenbacher
authors.forename: M
authors.initials: M
authors.lastname: Schumacher
authors.forename: B
authors.initials: B
authors.lastname: Eber
authors.forename: V
authors.initials: V
authors.lastname: Weinrauch
authors.forename: G M
authors.initials: GM
authors.lastname: Kostner
authors.forename: H
authors.initials: H
authors.lastname: Esterbauer
mesh_terms: D000368:Aged; D000375:Aging / Q000502:physiology; D017153:Antibodies, Anticardiolipin / Q000097:blood; D000975:Antioxidants / Q000378:metabolism; D001057:Apolipoproteins E / Q000235:genetics; D002545:Brain Ischemia / Q000150:complications / Q000175:diagnosis; D002561:Cerebrovascular Disorders / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D016015:Logistic Models; D008279:Magnetic Resonance Imaging; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012307:Risk Factors
chemical_list: D017153:Antibodies, Anticardiolipin; D000975:Antioxidants; D001057:Apolipoproteins E